Cyclosporine induces glomerulosclerosis: Three-dimensional definition of the lesions in a rat model of renal transplant  by Perico, Norberto et al.
Kidney International, Vol. 49 (1996), pp. 1283—1288
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Cyclosporine induces glomerulosclerosis: Three-dimensional definition
of the lesions in a rat model of renal transplant. Previous description of
chronic cyclosporine (CsA) renal toxicity cnmmonly included vascular
changes, tubular atrophy, and interstitial fibrosis. CIlomerular injury was
only occasinnally documented and it is not clear whether glomerular
changes may have an impact on the clinical syndrome of CsA toxicity
ohserved in experimental animals and humans. At the moment the
prevailing view is that when patients given CsA have glumerular lesions at
a renal biopsy, these were due to concomitant chrunie rejection or renal
hypnperfusion rather than to CsA itself. As a follow-up of our previnus
work on the subject (abstract; JAm Soc Nephrol 2:1398, 1992) the present
study was undertaken to clarify whether CsA is a direct cause of
glomerular injury. We used a model of renal transplant among Lewis rats
to better mimic the condition in which CsA is given to humans. Animals
underwent kidney isografts and were given daily CsA or vehicle for as long
as 12 months. At the end of the experiment specimens of renal tissue were
analyzed by a serial section morphometrie analysis technique, which allows
precise evaluation at the individual glomerular level, glomerular volume
and percentage of the capillary tuft affected by sclerosis. Among 85
glomeruli from CsA-treated rats, examined by three-dimensional morpho-
metric analysis, only 12% were normal and 88% revealed segmental
sclerosis. Data of single-section analysis compared with three-dimensional
morphometrie reconstruction showed that the former markedly underes-
timated the extent of glomerular injury. By three-dimensional analysis we
showed that chronic CsA administration was associated with profound
changes in glomerular capillary tuft volume distribution as compared to
normal. Specifically, a subset of smaller than normal glomeruli emerged in
CsA-treated animals in addition to a population of glomeruli which were
larger than normal. No significant correlation was found between capillary
tuft volume and sclerosis volume. These findings indicate that chronic
administration of CsA induces in rats glomerular lesions comparable to
the ones reported in human renal or heart transplant. Our present model
may help investigating the mechanism(s) of chronic CsA renal toxicity,
and will provide important clues for pharmacological manipulations aimed
at reducing the long-term consequences of CsA on the kidney.
Cyclosporine A (C5A) has clearly improved one-year allograft
survival in renal, liver, heart, and pancreas transplantation [1—4].
Recent studies have also convincingly documented that CsA is
beneficial for autoimmune diseases including uveitis [5], systemic
lupus erythematosus [6], rheumatoid arthritis [7], and various
forms of glomeruloncphritis [8, 9]. Although CsA indisputably
represents a major achievement of modern medicine as an
immunosuppressant, unfortunately there is clear evidence that it
induces renal injury [10—12]. Acute renal toxicity of CsA is mainly
related to afferent arteriole vasoeonstrietion that causes renal
hypoperfusion [13, 14]. This is a rapidly reversible phenomenon
and may not be of great concern in clinical practice [10—12]. Much
more relevant is chronic CsA renal toxicity that includes vascular
damage—the so-called CsA associated arteriolopathy—tubular at-
rophy and interstitial fibrosis [15]. Renal lesions of this kind have
been described in kidney [16], heart [17], liver [18], and bone
marrow [19] transplant recipients as well as in patients given CsA
for autoimmune diseases [20, 21]. In heart transplant patients two
years of CsA caused a decline in renal plasma flow (RPF) and
glomerular filtration rate (GFR) that was associated with signs of
renal structural damage [22, 23]. In addition to vascular and
tubulointerstitial changes, lesions have occasionally been de-
scribed in the glomeruli, like juxtaglomerular apparatus hyperpla-
sia, and thickening and wrinkling of capillary basement membrane
with finding of focal and segmental glomeruloselerosis [22, 23],
but the clinical significance of these findings has never been
clarified.
Animal studies of chronic CsA toxicity are few and incomplete
[24—30] and data available in the rat so far were not convincing
enough as to whether CsA really induced glomerular injury. Some
investigators therefore suggested that the rat were not the appro-
priate model to study glomerular lesions that may develop in
humans [31, 32]. Others based on the erratic findings in the rat
concluded that glomerular lesions in humans were not due to
CsA, but rather to concomitant chronic rejection (in cases of renal
transplant) or to renal hypoperfusion (as far as heart transplan-
tation was concerned) [33].
To clarify whether CsA is a direct cause of glomerular injury
independent of other factors, we took advantage of a model of
renal transplantation that mimics the condition in which CsA is
given to humans. To exclude lesions attributable to undergoing
rejection, transplants were performed in syngeneic animals, which
are immunologically compatible and do not reject. Renal speci-
mens taken from the same animals of the previous study [34] were
analyzed here by a serial section morphometric analysis technique
to evaluate glomerular volume and percentage of the capillary tuft
affected by sclerosis at individual glomerular levels [35].
Methods
Male inbred Lewis rats (Charles River Italia S.p.a., Calco Italy)
weighing 200 to 250 g at the start of the experiment were used.
They were fed standard rat chow and had free access to tap water.
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The study was conducted in accordance with the National Insti-
tute of Health Guide for the Care and Use of Laboratory
Animals.
Glomerular population
Two groups of glomeruli were analyzed: group 1 consisted of 85
glomeruli from CsA-treated rats, and group 2 included 68 gb-
meruli from vehicle-treated animals that were considered as
controls. This is a representative sample of CsA- and vehicle-
treated rats from our previous work aimed at examining the
impact of chronic CsA administration on renal function in rats
with kidney isograft [34]. In particular, glomeruli were obtained
from renal biopsies of seven Lewis rats that had undergone
orthotopic left kidney isograft from Lewis rats of the same sex and
strain and were given CsA for 12 months. These animals repre-
sented those in the CsA-treated group that survived over the
entire 12-month study period [34]. Each rat provided a compara-
ble number of glomeruli, namely 12, 10, 14, 12, 12, 9, and 16 for
rats #1, 2, 3, 4, 5, 6, and 7, respectively. Renal biopsy of six
similarly transplanted rats but given daily the CsA vehicle were
also examined [34]. Those animals were randomly chosen among
the original 12 that reached the end of the 12-month follow-up,
and thus glomeruli studied here were a representative sample of
the study group. Also in the control group, the number of
glomeruli studied from each animal was similar (13, 14, 10, 10, 11,
and 10 glomeruli for control rats #1, 2, 3, 4, 5, and 6, respectively).
Animals on CsA received the drug by gavage at the daily dose of
20 mg/kg (Sandoz, Basel, Switzerland). Control transplanted rats
were orally given polyoxyethylenated castor oil in which CsA was
dissolved.
Kidney isograft
Kidney transplant was performed as previously described [36].
Briefly, the left kidney was carefully removed from the donor rat
by transecting the ureter near the bladder junction, avoiding
injury to the blood supply. Then an aortic segment with the renal
artery was cut and made into a carrel patch. Similarly, the renal
vein was transected near the inferior vena cava. The kidney was
then placed in cold saline before transplantation. In the recipient,
a left nephrectomy was performed. The donor kidney was ortho-
topically transplanted by end-to-end renal vein anastomosis. The
renal artery was then anastomosed to the aorta with the small
patch of donor aorta. A ureterovesical anastomosis was per-
formed. The native right kidney of the recipient was removed.
Histological studies
At the end of the 12-month observation period renal tissue
specimens were processed for light microscopy by fixation in
Dubosq-Brazil fluid and embedded in paraffin. Serial sections
(from 70 to 90 sections, 3 sm thick) were cut on a microtome and
stained with periodic acid-Schifi"s reagent. Sections including
superficial and juxtamedullary glomeruli were evaluated. Histo-
logical examination aimed at detecting glomerular sclerotic le-
sions was performed by light microscopy. For each of the biospy
the number of normal, segmentally and globally sclerotic glomer-
uli was determined. Glomerular sclerosis was defined as an
increase in mesangial matrix substance associated with capillary
wall wrinkling and collapse. This was differentiated from hyalino-
sis lesions that were defined by the presence of PAS-positive
hyalin material included or separated by sclerotic regions in the
subendothelium or in the mesangium.
Morphometrical analysis
A section located approximately in the middle of the tissue,
hereafter referred to as the 'starting section,' was randomly
chosen for each kidney tissue fragment. Examination of all
sections preceding and following the starting section allowed us to
select the glomeruli entirely contained in the tissue fragment and
these were then subjected to three-dimensional morphometrical
analysis. Every section of each selected glomerulus was digitized
using a CCD video camera connected to the microscope and
transferred to a computer for digital processing with general
purpose image-processing software (Image 1.55, NIH, Bethesda,
MD, USA). For each section the profiles of capillary and sclerotic
areas were manually outlines using a polygonal line and the area
occupied by the polygon was automatically measured in screen
pixels. Exact enlargement was used for calculation of actual values
of measured surface area using digitized images of a calibration
grid, as previously described [37]. Volume of capillary tuft and
sclerotic regions for each glomerulus was calculated as:
where Ai, is the surface area of the outlines of capillary tuft and
glomerular sclerotic regions, d is the section thickness, and n is the
number of section for each glomerulus.
In addition, for each glomerulus defined as affected by a
sclerotic process the number of sections with sclerotic areas was
determined and these sections processed for evaluation of total
percentage of capillary tuft volume affected by sclerosis.
Three-dimensional reconstruction
Images of all the sections of each glomerulus representing the
glomerular tuft profiles and the profile of sclerotic areas, when
present, were used for three-dimensional projection. On the
images acquired from the microscope, the capillary tuft and areas
of sclerosis were outlines in each section. These outlines were
then used to create a side view, using a projection function, to
show the localization of sclerosis areas.
Renal function measurement
At the end of the 12-month follow-up, renal function was
assessed by measuring serum creatinine concentration in CsA-
and vehicle-treated rats. Moreover, all these animals underwent
renal clearance studies to determine GFR by inulin clearance, as
previously described [34]. At the same time point, urinary protein
excretion was determined in both groups of rats on samples
collected in individual metabolic cages during a 24 hour period.
Statistical analysis
Statistical analysis was performed using unpaired Student's
t-test or linear regression analysis. Statistical significance was
defined as P < 0.05. All data are expressed as means SD.
Results
Chronic treatment with CsA resulted in a decline in renal
function. Therefore, at the end of the 12-month observation
period serum creatinine was 1.38 0.15 mg/dl in rats given CsA,
a value significantly higher than that in vehicle-treated animals
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Table 1. Incidence of sclerosis according to single-section and serial-section morphologic analysis of glomerular structure in CsA- and vehicle-
treated rats
Single-section Serial-section
Segmental Global Segmental Global
N glomeruli Normal sclerosis sclerosis Normal sclerosis sclerosis
CsA 85 60 25 0 10 75 0
(100%) (70.5%) (29.4% (11.7%) (88.2%)a
Vehicle 68 68 0 0 58 10 0
(100%) (100%) (0%) (85.2%) (14.7%)
a p C 0.01 vs. vehicle
(0.75 0.09 mg/dl, P < 0.01). Similarly, GFR, measured as inulin
clearance, was significantly lower in CsA- than in vehicle-treated
rats (0.28 0.09 vs. 0.53 0.06 ml/min/100 g body wt, P C 0.01).
Renal function impairment was associated with increased urinary
protein excretion (CsA, 46 7; vehicle, 18 9 mg/24 hr; P C
0.01). Light microscopic findings of histological examination of
glomerular structure in CsA- and vehicle-treated rats are summa-
rized in Table 1. According to single-section analysis, in which
only the starting section was considered, in rats given CsA 29% of
glomeruli showed sclerotic lesions that were defined as segmental.
In vehicle-treated animals all glomeruli in the starting section
were classified as normal. By contrast, the incidence of glomeru-
losclerosis on serial section analysis of reconstructed glomeruli
was markedly different as compared with the results on single-
section evaluation. Thus in CsA-treated rats 88% of glomeruli
showed segmental sclerosis, while only 12% were found to be
completely free from the sclerotic process. Those affected by the
sclerotic lesions did belong from both superficial and juxtamed-
ullary glomeruli, that were equally involved by the process.
Similarly serial section analysis in rats given vehicle revealed that
10 glomeruli (15%), out of the 68 examined, presented signs of
sclerosis out of the starting section. Overall the frequency of
segmental glomerulosclerosis was significantly lower in CsA- than
in vehicle-treated rats (P C 0.01) after single-section or serial-
section analysis. In both groups of animals none of the glomeruli
examined were affected by global sclerosis.
Morphometrical analysis of glomerular volume showed no
significant difference in mean capillary tuft (CT) volume between
CsA and vehicle-treated rats (0.68 0.08 vs. 0.59 0.06 .tm3 X
10_a, respectively). However, the frequency distribution histo-
grams of CT volume was quite different in the two groups of
animals as shown in Figure 1. In vehicle-treated rats CT volume
was normally distributed around the mean. CsA treatment in-
duced profound changes in the normal distribution of glomerular
volume, in that CT volume distribution was spread toward both
smaller and larger size as compared with glomeruli from rats given
vehicle alone. Thus in CsA-treated rats the percentage of glomer-
uli with CT volume  0.3 gm3 X 10—6 was significantly higher
than in vehicle-treated rats (15% vs. 3%, P C0.05). Moreover, the
percentage of glomeruli with CT volume greater than 1.2 tm3 X
106 was significantly higher in CsA- than in vehicle-treated
animals (16% vs. 0%, P C 0.01). Similar results were found for the
pattern of distribution of Bowman's capsule volume.
In glomeruli from rats given CsA sclerosis volume was on
average 0.028 0.023 m3 X io (range 0 to 0.082). In these
animals sclerotic regions were confined to a fraction of the CT
volume that on average was 5.2 5.0% (range 0 to 22%). As
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Fig. 1. Frequency distribution histograms of capillaty tuft volume in glomer-
uli analyzed by serial-section reconstruction from transplanted rats given (A)
vehicle or (B) cyclosporine (CsA) for 12 months.
shown by the frequency distribution histogram reported in Figure
2 sclerosis volume was larger than 16% of the CT volume only in
few glomeruli, the majority of glomeruli being affected by sclerotic
changes in less than 10% of the CT volume.
In rats given vehicle the average sclerosis volume was signifi-
cantly lower than in CsA-treated rats (0.002 0.003 gm3 X 106,
range 0 to 0.006; P C 0.01). In the same animals only a very small
fraction of CT volume was affected by the sclerotic process (on
average 1.2 1.0%). Examined the frequency distribution of
percentage of glomerular CT volume affected by sclerosis, all the
sclerosis changes were confined in less than 4% of the CT volume
(Fig. 2).
Evaluating the relationship between CT volume and sclerosis
volume, no significant correlation was found between the two
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parameters in CsA- and vehicle-treated rats (CsA, r = 0.08, P =
0.702; vehicle, r = 0.06, P = 0.785).
As shown in Figure 3B, the glomeruli from CsA-treated animals
affected by sclerosis showed the sclerotic process distributed in
different areas of the capillary tuft suggesting that glomerular
injury developed as multifocal small lesions.
Discussion
The present study shows that rats undergoing renal isograft that
were given CsA for 12 months do develop massive glomeruloscie-
rosis as documented by three-dimensional serial-section recon-
struction of the entire glomerular capillary tuft. Comparing data
of single-section examination with the three-dimensional morpho-
metric reconstruction, we found that the former markedly under-
estimated the number of glomeruli affected by sclerosis as well as
the extent of sclerotic lesions within each glomerulus.
Additional serial section analysis of individual glomeruli in
CsA-treated animals allowed us to calculate glomerular volumes
and precisely define the extent of glomerular lesions as compared
to animals undergoing the same surgery but given vehicle alone.
Chronic CsA administration was associated with profound devia-
tion from normal of glomerular capillary tuft volume distribution
leading a subset of small glomeruli to emerge in addition to a
population of glomeruli which were definitely larger than normal.
It is possible that the subpopulation of smaller than normal
glomeruli reflected ischemic injury and collapse of the capillary
tuft. Glomeruli spared by the ischemic insult may enlarge as a
compensatory mechanism finalized to preserve glomerular filtra-
tion rate despite the subpopulation of ischemic nephrons that
lowers total filtration area. Glomerular volume distribution in rats
undergoing renal transplant but given vehicle for the same period
of time was comparable to previous data in normal rats [38].
Linear regression analysis of capillary tuft volume against glomer-
ular volume failed to show correlations between the two variable
at individual glomerular level in chronic CsA-treated animals.
Actually sclerotic areas were found both in large as well in small
glomeruli to a comparable extent.
Consistent with experimental findings presented here are data
that in humans with heart transplant given CsA for more than two
years, the normal bell-shaped distribution of glomerular capillary
volume was shifted to both smaller and larger size glomeruli [23].
In the above study in addition to changes in capillary tuft volume
distribution, three-dimensional reconstruction of individual gb-
meruli documented segmental and global sclerosis. It was specu-
lated that glomeruloscierosis were the consequence of CsA-
induced persistent afferent arteriolar vasospasm that would
impede glomerular perfusion to downstream gbomeruli resulting
in structural alteration [17, 39]. Whether these alterations were
irreversible and whether they solely reflected CsA toxicity, or
other factors were implicated, was a matter of active debate in the
last years [33]. This question could not be addressed in human
renal transplantation, since concomitant rejection or glomerular
lesions related to hypertension might have jeopardized the inter-
pretation of the biopsy finding. On the other hand, renal biopsy
material is difficult to obtain in heart or liver transplantation.
Also, the few available studies in heart transplant could not
completely rule out the possibility that concomitant nephrotoxic
drugs or heart dysfunction-induced relative renal hypoperfusion
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add to CsA in determining glomerular lesions [331. Old studies
that addressed whether CsA directly caused renal structural
damage in experimental animals failed to demonstrate glomerular
lesions in normal rats. Therefore, in Sprague-Dawley rats given
oral CsA for up to 84 days tubulointerstitial lesions, but not
primary glomerular lesions, were found [401. Similarly, no evi-
dence of glomerular injury was observed in rats treated with daily
oral CsA for 16 weeks [26]. In another study in Sprague-Dawley
rats, administration of CsA by gavage on every other day for five
months resulted in glomerular endothelial damage, glomerular
hypercellularity and mesangial matrix expansion that, however,
were very mild in nature [241. Moreover, in Munich Wistar rats
given oral high dose CsA for three weeks hypertrophy of the
juxtaglomerular apparatus was seen [301. On the other hand, mild
focal segmental mesangial sclerosis, wrinkling, and thickening of
glomerular capillary walls were documented in few glomeruli
from Sprague-Dawley rats receiving CsA intraperitoneally for 28
consecutive days [25]. However, these changes were minor and
did not differ from those found in pair-fed vehicle-treated control
animals. These studies were taken to suggest that the rat was not
an appropriate model for the corresponding glomerular disease in
humans [31, 32].
By contrast, the present study shows that rats have glomerulo-
sclerosis after one year of CsA, and that the lesions are quite
comparable to those of transplant patients. To explain the dis-
crepancy one has to take into account that length of follow-up was
considerably longer in the present as compared to previous
experimental renal toxicity studies, in addition to the different
detection power of the three-dimensional reconstruction com-
pared to conventional-type analysis.
Therefore, the rat is a good model to study the long-term
consequences of CsA on the kidney.
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gO Fig. 3. Schematic representation of spalialdistribution of sclerotic lesions within each
individual glomendus in biopsy from vehicle- (A')
and CsA- (B) treated rats. Glomerular capillary
tuft and sclerotic areas are projected parallel to
the section plane. The line represents the
projection of the starting section.
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